


IMPROVING HEALTH EQUITY THROUGH PHARMACY INITIATIVES

Troy Shirley, PharmD, MBA
System Director of Pharmacy
Bronson Healthcare



Goals for today include


- Reviewing the Bronson pharmacy supported discharge initiatives
- Understanding our Bronson outcomes
- Where are we going next





Bronson Healthcare

- Regional, not-for-profit health system
- Locally owned and governed
- Serving southwest Michigan since 1900
- 8,600 employees
- 1,500 medical staff
- 4 hospitals: Battle Creek, Kalamazoo, Paw Paw and South Haven
- 796 licensed beds






Discharge Program

- Medication Reconciliation (discharge)
 - Unit based pharmacist reconciles all medications prior to discharge for targeted disease states of: COPD, pneumonia, heart failure, and AMI

- Unit based meds to beds program
 - Retail pharmacist and pharmacy technician collaborate with unit nurses and care managers to identify patients of interest
 - Medications fulfilled by a Bronson Outpatient Pharmacy
 - Medications hand delivered prior to discharge
 - Pharmacist performs medication counseling




Discharge Program






First assessment of program impact done in 2018





How to Prevent Readmissions



Discharge Medication Reconciliation

- 2016
 - Discharge Med Rec Navigator built in Epic
 - Pharmacists completed DMRs when able with high risk patients being top priority
 - High risk patients based on Risk for Readmission (R4R) score
 - EMR calculated risk score for 30-day readmission
 - Points determined from certain "triggers"

Score from 0-13	
- 0-3 low risk	
- 4-6 medium/ rising risk	
- 7-13 high risk	



R4R Score Triggers

- Past admission within 30-days
- Psychosocial risk
- Advanced Illness Management
 - Palliative care consult
- · No primary care provider



R4R Score Triggers

Medications	Diagnosis
Anticoagulants Insulin Dual antiplatelet therapy Digoxin Chronic narcotic use	Heart failure Pneumonia Stroke Cardiovascular disease COPD Diabetes Chronic kidney disease Metabolic encephalopathy Delirium




Discharge Medication Reconciliation

- 2017 Discharge medication reconciliation program adjusted
 - Initially focused on high-risk patients as identified by risk for readmission (R4R) tool
 - Trigger in EMR identified high-risk patients for the pharmacist to review
 - 6 months of experience identified gap in tool that was not identifying the highest-risk patients (CHF, pneumonia, COPD, stroke)
 - Tool redeveloped to focus on targeted disease states





THE IMPACT OF DISCHARGE MEDICATION RECONCILIATIONS ON 30-DAY READMISSION RATES




- Retrospective study design
- Data collected from EMR of patients discharged from Bronson Methodist Hospital
- ~20,000 patients in the data set study period
 - 2016 process (R4R only): July December 2016
 - 2017 process (Targeted + High Risk): July December 2017



R4R vs. Targeted Model

Readmission Rates of All Patients with a DMR




No difference between groups, with a trend to a lower readmission rate using just the R4R tool.





Primary Outcome

Readmission Rates of <u>High Risk</u> and <u>Targeted</u> Patients with a DMR




Overall readmission rates are worse when filtered to high risk, but better readmission rates by using the targeted model.






Primary Outcome

Readmission Rates of <u>High Risk</u> and <u>Targeted</u> Patients with a DMR






The Meds to Beds Program



What about those patients that also participated in our discharge prescription program (Meds to Bed)?



The Meds to Beds Program



Conclusion...

- Pharmacist involvement with medication reconciliation of high risk and targeted disease state patients at discharge provided a 7% reduction in 30 day readmissions over high risk patients alone.
- Trend toward additional reduction in readmission rates for all patients participating in the Meds to Beds program, but maybe not for high risk and targeted disease state patients.





EFFECT OF MEDS TO BEDS PROGRAM ON 30 DAY READMISSIONS

Bronson Methodist Hospital
Kalamazoo, MI
Allie Kelly, PharmD*

Andrew Johnson, PharmD James Curtis, PharmD, BCPS

Acknowledgements: Todd Walroth, PharmD, BCCCP, BCPS, FCCM
Adam Warner, PharmD

DISCLOSURE: the speaker has no actual or potential conflict of interest in relation to this presentation

Study design

Retrospective chart review

Groups

15

Meds to beds vs control

Study period

January 1st 2018 through December 31st 2021



Primary outcome


 Difference in 30 day readmission rate between those who utilized the meds to beds program and the control group

Secondary outcomes

- Readmission rates stratified by care area Difference in 30 day readmission for those with targeted disease states who utilized the meds to beds program vs the
- Sub-analysis of the high risk for readmission categories



17





20

BRONSON

Post-hoc analysis


30 day readmission rate for patients with 2+ targeted disease states

M2B (n=1403) Control (n=3629)

15.8% 13.9%

P = 0.092

- Key Findings
 - Med to Beds program provided no impact on 30 day readmission rates.





Patient demographics

	M2B (n=8504)	Control (n=17,667)
Age - median (IQR)	61 (49 - 71)	64 (52 - 74)
Gender – Female	4101 (48.2%)	8331 (47.4%)

Race

White or Caucasian	83.69%	85.19%
Black or African American	12.30%	10.51%
Something else	0.94%	1.01%
Other	0.80%	0.81%
American Indian or Alaska Native	0.80%	0.78%
Other (Hispanic, Latino/a)	0.53%	0.81%
Unknown	0.40%	0.19%
Asian	0.27%	0.23%
Choose not to disclose	0.13%	0.16%
Not Listed	0.13%	0.12%
Native Hawaiian or Other Pacific Islander	0.00%	0.04%
Other Pacific Islander	0.00%	0.08%
Arab	0.00%	0.08%

E.J. Witcraft, et al (2020)

- Single-center retrospective study
- Patient population: Patients admitted for at least 2 days and discharged from select services
 - Treatment n=790
 - Control n=2326
- Treatment: Pharmacy technician led medication bedside delivery program

Primary outcome	Results	Limitations
Readmission rate between treatment	Treatment: 7.97% Control: 10.09%	Single center study Matched by treatment
and control group	p=0.136	location not diagnosis





J. Segal, et al (2020)

- Retrospective study at multiple hospitals across Maryland
- Patient population: Patients admitted to the hospital
 - Treatment n=6,167
 - Control n=28,546
- Treatment: Medication to bedside delivery service

Primary outcome	Results	Limitations
Readmission rate between treatment and control group	Risk ratio for readmission: 1.21 (CI= 0.96 - 1.5)	Possible that treatment group was higher risk for readmission



Therefore, what do we know to date?

- Pharmacist involvement with discharge med rec impacts 30 day readmissions.
- Ours Meds to Beds results are consistent with recently published literature.
- Ours Meds to Beds program, as constructed, does not seem to have an impact on 30 day readmissions.



Where do we go from here?

- Pilot project with COPD patients initiated in early 2022
 - Provide rescue medications (5 day supply of prednisone + rescue inhaler) along with comprehensive education at discharge
 - Results pending
- Compare our Bronson Methodist Hospital data (presented today) with Bronson Battle Creek data (pending)
- Critically evaluate the construct of our program:
 - Are we targeting the correct areas of the hospitals?
 - Are we providing the correct medications? Should we provide them in a different way?
 - Should we be targeting different groups of patients?
 - Do we refocus the program entirely?



